Difference between revisions of "Nintedanib (Vargatef)"
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 16: | Line 16: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
[[Category:FGFR inhibitors]] | [[Category:FGFR inhibitors]] | ||
Revision as of 22:56, 28 February 2020
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3).
Diseases for which it is used
History of changes in FDA indication
Not FDA approved at this time.
Also known as
- Code name: BIBF 1120
- Brand names: Ofev, Vargatef